Literature DB >> 3456281

Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.

G Zini, G P Vicario, M Lazzati, F Arcamone.   

Abstract

The disposition of [14-14C]4-demethoxydaunorubicin HCl ([14-14C]idarubicin HCl, [14C]IDR) and of [14-14C]daunorubicin HCl ([14C]DNR) was studied in male Sprague Dawley rats. [14C]IDR was administered either IV at 0.25 mg/kg body weight or PO at 1 mg/kg body weight, whereas [14C]DNR was dosed IV at 1 mg/kg body weight. The main elimination route for both compounds was the bile, fecal excretion representing 0.75-0.8 times the total dose at 72 h. Radioactivity due to [14C]IDR-derived species is released by the tissues at a slower rate than activity derived from [14C]DNR. After IV treatment comparable plasma levels are obtained, but tissue radioactivity is markedly lower with [14C]IDR, in keeping with the lower dosage. The ratio of plasma to tissue radioactivity is even higher in animals treated PO with [14C]IDR, because of the more extensive metabolism after this route of administration. The 13-dihydro derivatives of both [14C]IDR and [14C]DNR are the main metabolites in tissues, but in the case of the former, products of phase II reactions become more important at later times in liver and kidney and in excreta.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456281     DOI: 10.1007/BF00256158

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Daunorubicin biliary excretion and metabolism in the rat.

Authors:  J C Cradock; M J Egorin; N R Bachur
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-03

2.  Identification of new metabolites of daunomycin and adriamycin.

Authors:  F J Bullock; R J Bruni; M A Asbell
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

3.  Distribution of tritiated daunomycin (NSC-82151) in normal rats.

Authors:  A Rusconi; G Di Fronzo; A Di Marco
Journal:  Cancer Chemother Rep       Date:  1968-04

4.  Daunomycin metabolism in rat tissue slices.

Authors:  N R Bachur; J C Cradock
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

5.  Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.

Authors:  F Arcamone; L Bernardi; P Giardino; B Patelli; A Marco; A M Casazza; G Pratesi; P Reggiani
Journal:  Cancer Treat Rep       Date:  1976-07

6.  Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Authors:  F Formelli; A M Casazza; A Di Marco; A Mariani; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Daunorubicin metabolism: estimation of daunorubicin reductase.

Authors:  N R Bachur; D H Huffman
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

9.  Initial biotransformations of daunorubicin to aglycones by rat liver microsomes.

Authors:  H S Schwartz; N B Parker
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

10.  Cardiomyopathy of doxorubicin in experimental animals, Factors affecting the severity, distribution and evolution of myocardial lesions.

Authors:  E Solcia; L Ballerini; O Bellini; U Magrini; C Bertazzoli; G Tosana; L Sala; F Balconi; F Rallo
Journal:  Tumori       Date:  1981-10-31
View more
  1 in total

1.  Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.

Authors:  B J Cusack; S P Young; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.